Unwrapping the genomic characteristics of urothelial bladder cancer and successes with immune checkpoint blockade therapy
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Unwrapping the genomic characteristics of urothelial bladder cancer and successes with immune checkpoint blockade therapy
Authors
Keywords
-
Journal
Oncogenesis
Volume 7, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-01-22
DOI
10.1038/s41389-017-0013-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology
- (2017) Philippe E. Spiess et al. Journal of the National Comprehensive Cancer Network
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
- (2017) Arjun V Balar et al. LANCET
- Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
- (2017) Matthew D Hellmann et al. LANCET ONCOLOGY
- First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
- (2017) Arjun V Balar et al. LANCET ONCOLOGY
- Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis
- (2017) Alexandra Snyder et al. PLOS MEDICINE
- Systemic Immunotherapy for Urothelial Cancer: Current Trends and Future Directions
- (2017) Shilpa Gupta et al. Cancers
- Pembrolizumab (pembro) as first-line therapy for advanced/unresectable or metastatic urothelial cancer: Preliminary results from the phase 2 KEYNOTE-052 study
- (2016) A. Balar et al. ANNALS OF ONCOLOGY
- Burden of Nonsynonymous Mutations among TCGA Cancers and Candidate Immune Checkpoint Inhibitor Responses
- (2016) Leandro M. Colli et al. CANCER RESEARCH
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
- (2016) Willy Hugo et al. CELL
- Safety, clinical activity, and PD-L1 expression of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic urothelial carcinoma from the JAVELIN Solid Tumor phase Ib trial.
- (2016) Andrea B. Apolo et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
- (2016) Christophe Massard et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial
- (2016) Padmanee Sharma et al. LANCET ONCOLOGY
- Systemic anti-CTLA-4 and intravesical Bacille–Calmette–Guerin therapy in non-muscle invasive bladder cancer: Is there a rationale of synergism?
- (2016) Omar Fahmy et al. MEDICAL HYPOTHESES
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
- (2016) N. McGranahan et al. SCIENCE
- Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy
- (2016) T. M. Johanns et al. Cancer Discovery
- Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guérin therapy in bladder cancer
- (2016) Renate Pichler et al. Oncotarget
- Somatic Mutations and Neoepitope Homology in Melanomas Treated with CTLA-4 Blockade
- (2016) Tavi Nathanson et al. Cancer Immunology Research
- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Defects in DNA repair genes and sensitivity to cisplatin based neoadjuvant chemotherapy (NAC) for bladder cancer.
- (2015) Elizabeth R. Plimack et al. JOURNAL OF CLINICAL ONCOLOGY
- From the genomic frontier to immunotherapeutics
- (2015) Andrew T. Lenis et al. Nature Reviews Urology
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoantigens in cancer immunotherapy
- (2015) T. N. Schumacher et al. SCIENCE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy
- (2015) Mihaela Angelova et al. GENOME BIOLOGY
- Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival
- (2014) S. D. Brown et al. GENOME RESEARCH
- Targeting CD137 enhances the efficacy of cetuximab
- (2014) Holbrook E. Kohrt et al. JOURNAL OF CLINICAL INVESTIGATION
- Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy
- (2014) Xiaozhou Fan et al. JOURNAL OF EXPERIMENTAL MEDICINE
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with T Cell Clonotype Stability After Anti-CTLA-4 Treatment in Cancer Patients
- (2014) E. Cha et al. Science Translational Medicine
- CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients
- (2013) P. A. Ott et al. CLINICAL CANCER RESEARCH
- Prevalence and Co-Occurrence of Actionable Genomic Alterations in High-Grade Bladder Cancer
- (2013) Gopa Iyer et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Identification of Nine Genomic Regions of Amplification in Urothelial Carcinoma, Correlation with Stage, and Potential Prognostic and Therapeutic Value
- (2013) Yvonne Chekaluk et al. PLoS One
- Increased Frequency of ICOS+ CD4 T Cells as a Pharmacodynamic Biomarker for Anti-CTLA-4 Therapy
- (2013) D. Ng Tang et al. Cancer Immunology Research
- Combined Targeting of Costimulatory (OX40) and Coinhibitory (CTLA-4) Pathways Elicits Potent Effector T Cells Capable of Driving Robust Antitumor Immunity
- (2013) W. L. Redmond et al. Cancer Immunology Research
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Integrated Genomic and Gene Expression Profiling Identifies Two Major Genomic Circuits in Urothelial Carcinoma
- (2012) David Lindgren et al. PLoS One
- An immune-active tumor microenvironment favors clinical response to ipilimumab
- (2011) Rui-Ru Ji et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- CD8+ T Cells Specific for Tumor Antigens Can Be Rendered Dysfunctional by the Tumor Microenvironment through Upregulation of the Inhibitory Receptors BTLA and PD-1
- (2011) J. Fourcade et al. CANCER RESEARCH
- VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
- (2011) Li Wang et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting
- (2010) Geoffrey Y. Ku et al. CANCER
- Gene Signature in Melanoma Associated With Clinical Activity
- (2010) Thomas F. Gajewski et al. CANCER JOURNAL
- Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+T cell dysfunction in melanoma patients
- (2010) Julien Fourcade et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium
- (2010) Guru Sonpavde et al. LANCET ONCOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
- (2009) Karl S. Peggs et al. JOURNAL OF EXPERIMENTAL MEDICINE
- CTLA-4 blockade increases IFN -producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients
- (2008) C. I. Liakou et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Intravesikale Therapie nicht muskelinvasiver Blasentumoren mit onkolytischen Vesikular-Stomatitisviren
- (2008) B.A. Hadaschik et al. UROLOGE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started